WO2000037057A3 - Novel formulations comprising lipid-regulating agents - Google Patents

Novel formulations comprising lipid-regulating agents Download PDF

Info

Publication number
WO2000037057A3
WO2000037057A3 PCT/US1999/029696 US9929696W WO0037057A3 WO 2000037057 A3 WO2000037057 A3 WO 2000037057A3 US 9929696 W US9929696 W US 9929696W WO 0037057 A3 WO0037057 A3 WO 0037057A3
Authority
WO
WIPO (PCT)
Prior art keywords
lipid
regulating agents
novel formulations
formulation
regulating
Prior art date
Application number
PCT/US1999/029696
Other languages
French (fr)
Other versions
WO2000037057A2 (en
Inventor
John M Lipari
Dawn M Raymond
Tom Reiland
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Priority to JP2000589168A priority Critical patent/JP2002532539A/en
Priority to CA002355820A priority patent/CA2355820A1/en
Priority to EP99967317A priority patent/EP1140036A2/en
Publication of WO2000037057A2 publication Critical patent/WO2000037057A2/en
Publication of WO2000037057A3 publication Critical patent/WO2000037057A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Abstract

The present invention is directed to a formulation comprising a lipid-regulating agent dissolved in at least one propylene glycol fatty acid ester as the primary solvent medium for said agent. One or more emulsifiers may be added to the formulation.
PCT/US1999/029696 1998-12-18 1999-12-15 Novel formulations comprising lipid-regulating agents WO2000037057A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2000589168A JP2002532539A (en) 1998-12-18 1999-12-15 Novel formulations containing lipid modulators
CA002355820A CA2355820A1 (en) 1998-12-18 1999-12-15 Novel formulations comprising lipid-regulating agents
EP99967317A EP1140036A2 (en) 1998-12-18 1999-12-15 Novel formulations comprising lipid-regulating agents

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21644898A 1998-12-18 1998-12-18
US09/216,448 1998-12-18

Publications (2)

Publication Number Publication Date
WO2000037057A2 WO2000037057A2 (en) 2000-06-29
WO2000037057A3 true WO2000037057A3 (en) 2000-11-16

Family

ID=22807109

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/029696 WO2000037057A2 (en) 1998-12-18 1999-12-15 Novel formulations comprising lipid-regulating agents

Country Status (4)

Country Link
EP (1) EP1140036A2 (en)
JP (1) JP2002532539A (en)
CA (1) CA2355820A1 (en)
WO (1) WO2000037057A2 (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8865695B2 (en) 2009-01-08 2014-10-21 Lipocine Inc. Steroidal compositions
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US9498485B2 (en) 2014-08-28 2016-11-22 Lipocine Inc. Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6372251B2 (en) * 1999-06-11 2002-04-16 Abbott Laboratories Formulations comprising lipid-regulating agents
US6982281B1 (en) 2000-11-17 2006-01-03 Lipocine Inc Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
US7276249B2 (en) 2002-05-24 2007-10-02 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
WO2002100394A1 (en) * 2001-06-12 2002-12-19 Galephar M/F Oral pharmaceutical composition containing a statin derivative
FR2827770B1 (en) * 2001-07-27 2005-08-19 Gattefosse Ets Sa ORAL PHARMACEUTICAL COMPOSITION COMPRISING AN ACTIVE INGREDIENT LIKELY TO BE SUBSTANTIALLY EFFECT OF FIRST INTESTINAL PASSAGE
CA2576196A1 (en) 2004-08-06 2006-02-16 Transform Pharmaceuticals, Inc. Novel statin pharmaceutical compositions and related methods of treatment
US20060188529A1 (en) * 2004-12-06 2006-08-24 George Bobotas Stable compositions of fenofibrate with fatty acid esters
CN101495150B (en) * 2006-08-01 2011-06-01 大塚制药株式会社 Pharmaceutical composition improved in absorption of pharmacologically active substance
JP2013047282A (en) * 2006-08-31 2013-03-07 Aska Pharmaceutical Co Ltd Fenofibrate-containing composition
JP5186159B2 (en) * 2006-08-31 2013-04-17 あすか製薬株式会社 Fenofibrate-containing composition
WO2010047361A1 (en) * 2008-10-22 2010-04-29 参天製薬株式会社 Pharmaceutical composition improved in absorption through intestinal tract
EP2400840A4 (en) * 2009-02-24 2012-08-01 Madeira Therapeutics Liquid statin formulations
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
US20170246187A1 (en) 2014-08-28 2017-08-31 Lipocine Inc. (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
KR20170115071A (en) 2015-02-06 2017-10-16 인터셉트 파마슈티컬즈, 인크. Pharmaceutical compositions for combination therapy
EP3544614A4 (en) 2016-11-28 2020-08-05 Lipocine Inc. Oral testosterone undecanoate therapy

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992010996A1 (en) * 1990-12-18 1992-07-09 Merrell Dow Pharmaceuticals Inc. Enhanced bioavailability pharmaceutical composition containing probucol
WO1995014463A1 (en) * 1993-11-25 1995-06-01 Taisho Pharmaceutical Co., Ltd. Composition of pharmaceutical preparation improved in peroral absorbability
US5645856A (en) * 1994-03-16 1997-07-08 R. P. Scherer Corporation Delivery systems for hydrophobic drugs
EP0998927A1 (en) * 1998-10-30 2000-05-10 Fujirebio Inc. Absorption-enhancing composition for pantothenic acid derivative

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992010996A1 (en) * 1990-12-18 1992-07-09 Merrell Dow Pharmaceuticals Inc. Enhanced bioavailability pharmaceutical composition containing probucol
WO1995014463A1 (en) * 1993-11-25 1995-06-01 Taisho Pharmaceutical Co., Ltd. Composition of pharmaceutical preparation improved in peroral absorbability
US5645856A (en) * 1994-03-16 1997-07-08 R. P. Scherer Corporation Delivery systems for hydrophobic drugs
EP0998927A1 (en) * 1998-10-30 2000-05-10 Fujirebio Inc. Absorption-enhancing composition for pantothenic acid derivative

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DATABASE CHEMABS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; KOUJI, MINORU ET AL: "Composition of pharmaceutical preparation improved in peroral absorbability", XP002144199, retrieved from STN Database accession no. 123:152928 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8865695B2 (en) 2009-01-08 2014-10-21 Lipocine Inc. Steroidal compositions
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US9205057B2 (en) 2010-11-30 2015-12-08 Lipocine Inc. High-strength testosterone undecanoate compositions
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US9480690B2 (en) 2010-11-30 2016-11-01 Lipocine Inc. High-strength testosterone undecanoate compositions
US9498485B2 (en) 2014-08-28 2016-11-22 Lipocine Inc. Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters

Also Published As

Publication number Publication date
WO2000037057A2 (en) 2000-06-29
CA2355820A1 (en) 2000-06-29
EP1140036A2 (en) 2001-10-10
JP2002532539A (en) 2002-10-02

Similar Documents

Publication Publication Date Title
WO2000037057A3 (en) Novel formulations comprising lipid-regulating agents
CA2185308A1 (en) Ester-based cleaning compositions
EP0983273B8 (en) Ethylene glycol esters of monohydrobenzoporphyrin derivatives as photoactive agents
CA2141433A1 (en) Nonflammable Mild Odor Solvent Cleaner
WO2001074331A1 (en) Oily compositions containing highly fat-soluble drugs
EP1073439A4 (en) Pharmaceutical composition
DK0823895T3 (en) Fatty acid esters as bioactive compounds
AU7974994A (en) Liquid detergent compositions comprising salts of alpha sulfonated fatty acid methyl esters, and anionic surfactants
HUP0002486A1 (en) Self-emulsifying formulation for lipophilic compounds
DE59300931D1 (en) Nonionic, flowable pearlescent dispersions.
AU3124400A (en) Wax compositions comprising fatty ester poly(oxyalkylenated) colorants
CA2172148A1 (en) Non-toxic biodegradable emulsion compositions for use in automatic car washes
EP0895777A3 (en) Compositions based on peroxyacids
AR023000A1 (en) TENSIOACTIVE AGENTS FOR USE IN FORMULATIONS FOR AGRICULTURE
CA2343130A1 (en) Cosmetic composition
CA2313878A1 (en) Composition for suppressing behavior problems of pets
NO990435D0 (en) Preparation of Esters as Surfactants
IL111872A0 (en) Pharmaceutical compositions comprising a staurosporine as active ingredient
EP1106167A3 (en) Dye compositions for keratin fibers comprising a nonionic compound
DE69701530T2 (en) BLOCK COMPOSITIONS WITH LOW FATTY ACID SOAPS
NO20003105D0 (en) Phenylaminoalkylcarboxylic acid derivatives as well as medical compositions comprising such
IL126185A0 (en) Compositions comprising an hiv protease inhibitor such as vx 478 and a water soluble vitamin e compound such as vitamin e-tpgs
AU2695595A (en) Polyphenolic vegetable extract/surfactant compositions as universal bitumen/water emulsifiers
WO1995023586A3 (en) Cosmetic and/or pharmaceutical preparations
GB2349336B (en) Pesticidal composition based on 2-methoxycarbonyl-4-chlorotrifluoromethanesulphonanilide & an ester of an alkanedicarboxylic, citric or fatty acid

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): CA JP MX

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): CA JP MX

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

WWE Wipo information: entry into national phase

Ref document number: 1999967317

Country of ref document: EP

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 589168

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase

Ref document number: 2355820

Country of ref document: CA

Ref country code: CA

Ref document number: 2355820

Kind code of ref document: A

Format of ref document f/p: F

WWP Wipo information: published in national office

Ref document number: 1999967317

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1999967317

Country of ref document: EP